ATM is frequently mutated in prostate cancer [68], as well as somatic and hereditary forms of pancreatic cancers [69,70], suggesting that patients with these cancers might also benefit from treatment with a PARP inhibitor. This evidence concerns the gene ATM and pancreatic neoplasm.